Cincinnati plays host to new cell, viral vector manufacturing site from Expression Therapeutics
Expression Therapeutics’ new cell and viral vector manufacturing site is up and running in Cincinnati.
The 43,000 square-foot site will provide end-to-end R&D capabilities and both early phase- and commercial-scale manufacturing of lentiviral and adeno-associated viral vectors. The site will have a mix of 30-180 liter runs in cell stacks and up to 1,000 liter runs in bioreactors, with the capability to manufacture up to 100 products per year. It also gives the necessary infrastructure to fulfill its ex vivo cell processing, and recombinant protein production needs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.